Related Experiment Videos
Novel antibody drug products
J T DiPiro1, R G Hamilton, J P Wei
1University of Georgia College of Pharmacy, Augusta.
American Journal of Surgery
|July 1, 1992
Summary
Engineered antibody therapeutics offer new treatment options for diseases. However, clinicians must consider potential adverse effects, immunogenicity, and cost implications for these advanced antibody drugs.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Murine monoclonal antibodies have therapeutic limitations, including immunogenicity and suboptimal efficacy.
- Protein and genetic engineering advances enable novel antibody-derived therapeutics.
- Engineered antibodies show promise beyond traditional applications, including oncology and infectious diseases.
Purpose of the Study:
- To review the development and therapeutic potential of engineered antibody molecules.
- To highlight the clinical considerations associated with novel antibody drug products.
Main Methods:
- Review of recent advancements in protein and genetic engineering for antibody development.
- Analysis of therapeutic applications and clinical challenges of engineered antibodies.
Main Results:
- Engineered antibodies include human monoclonal antibodies, chimeric antibodies, CDR-grafted antibodies, and immunotoxins.
- These novel antibodies are investigated for infectious diseases, cancers, and non-traditional indications like antithrombotics.
- Clinical use necessitates attention to adverse effects, immunogenicity, dosing, and cost.
Conclusions:
- Engineered antibodies represent a significant advancement in therapeutic development.
- Careful clinical management is crucial to address safety, efficacy, and economic factors associated with these novel agents.